Diffusion-weighted imaging is a sensitive biomarker of response to biologic therapy in enthesitis-related arthritis by Bray, TJP et al.
 1 
Diffusion-weighted imaging is a sensitive biomarker of 
response to biologic therapy in enthesitis-related 
arthritis 
Original Research 
1,2Timothy JP Bray  
1Kanimozhi Vendhan  
2Nicola Ambrose 
1David Atkinson  
1Shonit Punwani  
2Corinne Fisher 
2Debajit Sen MBBS 
2Yiannis Ioannou  
1Margaret A Hall-Craggs  
1UCL Centre for Medical Imaging (Academic Radiology), 3rd floor East 250 Euston Road, London. NW1 2PG 
2Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London.  
 
Corresponding author:  
Timothy JP Bray t.bray@ucl.ac.uk  0203 447 9324 
Keywords: Magnetic resonance imaging, Diffusion-weighted Imaging, Spondyloarthritis, 
Juvenile Idiopathic Arthritis, Biomarkers 
 
This work was undertaken at UCLH/UCL, which receives funding from the Department of 
Health’s the National Institute for Health Research (NIHR) Biomedical Research Centre 
(BRC) funding scheme. The views expressed in this publication are those of the authors and 
not necessarily those of the UK Department of Health. MHC, SP, TJPB, YI are supported by 
the NIHR University College London Hospitals BRC and YI is also supported by Arthritis 
Research UK Grant 20164. 
 
 2 
Word count: 3,200 
Diffusion-weighted imaging is a sensitive biomarker of 
response to biologic therapy in enthesitis-related 
arthritis 
 
ABSTRACT 
Objective: To evaluate diffusion-weighted imaging (DWI) as a tool for measuring treatment 
response in adolescents with enthesitis-related arthropathy (ERA).  
 
Methods: 22 adolescents with ERA underwent routine MRI and DWI before and after tumour 
necrosis factor inhibitor (TNFi) therapy. Each patient’s images were visually scored by two 
radiologists using the Spondyloarthritis Research Consortium of Canada (SPARCC) system, 
and sacroiliac joint apparent diffusion coefficient (ADC) and normalized ADC (nADC) were 
measured for each patient. Therapeutic clinical response was defined as an improvement of 
≥30% physician global assessment and radiological response defined as ≥2.5-point drop in 
SPARCC score. We compared ADC and nADC changes in responders and non-responders 
using the Mann-Whitney-Wilcoxon test. 
Results: For both radiological and clinical definitions of response, reductions in ADC and 
nADC after treatment were greater in responders than in non-responders (for radiological 
response: ADC: p<0.01; nADC: p=0.055; for clinical response: ADC: p=0.33; nADC: p=0.089). 
ADC and nADC could predict radiological response with a high level of sensitivity and 
specificity, and were moderately sensitive and specific predictors of clinical response (the 
area under the receiver operating characteristic curves were ADC: 0.97, nADC: 0.82 for 
radiological response and ADC: 0.67, nADC: 0.78 for clinical response). 
 
Conclusion: DWI measurements reflect response to TNFi treatment in ERA patients with 
sacroiliitis as defined using radiological criteria, and may also reflect clinical response. DWI is 
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more objective than visual scoring, and has the potential to be automated. ADC/nADC could 
be used as biomarkers of sacroiliitis in the clinic and in clinical trials.  
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Key Messages 
 Diffusion-weighted imaging can be used to measure therapeutic response in 
enthesitis-related arthritis 
 Diffusion-weighted imaging is more objective than visual scoring as a measure of 
sacroiliitis in enthesitis-related arthritis 
 Quantitative imaging could be used to guide treatment decisions in the clinic in 
enthesitis-related arthritis 
 
Running title 
Diffusion-weighted imaging as a response biomarker in enthesitis-related arthritis 
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INTRODUCTION 
Enthesitis-related arthritis (ERA) is a juvenile-onset spondyloarthritis associated with severe 
pain, stiffness and disability, which accounts for ~20% of all adolescents and young adults 
with childhood-onset arthritis (1,2). Inflammation of the sacroiliac joints (sacroiliitis) is a 
common feature of ERA. Unlike other subtypes of juvenile idiopathic arthritis (JIA), ERA 
almost always progresses into adult life (3). Early treatment in spondyloarthritis has been 
shown to have a disease-modifying effect with consequently good outcomes (4), but if 
treatment is inadequate then outcomes are poor (3). Importantly, inflammatory and 
biomechanical back pain may co-exist in the same patient and it may be challenging to 
differentiate between the two in young patients with ERA/spondyloarthritis. A reliable, 
quick and cheap tool that could enhance confidence of adequate treatment and inflammatory 
control in early disease would therefore be clinically useful, especially in childhood onset or 
early adult-onset spondyloarthritis. 
 
Clinical evaluation is helpful in assessing disease activity, but has some limitations given that 
standard inflammatory blood markers may be normal in active disease (5,6). Clinical 
assessment of sacroiliitis specifically is also somewhat unreliable (7,8).  Furthermore, disease 
activity measures in spondyloarthritis are may vary substantially over repeated 
measurements (9) and have not been prospectively validated in childhood-onset 
spondyloarthritis.  
 
In clinical practice, radiologists typically assess bone marrow oedema on short tau inversion 
recovery (STIR) images. However, these scans only allow for qualitative assessment – i.e. they 
rely on subjective assessment of the images by the interpreting radiologist. Similarly, the 
Spondyloarthritis Research Consortium of Canada (SPARCC) (10) system requires a specialist 
radiologist to assign an overall inflammation ‘score’. The SPARCC score contains a number of 
subjective elements including assessment of the depth and brightness of inflammation and 
the number of inflamed joint quadrants. Furthermore, observers can only make binary 
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choices for each joint quadrant, which is unsatisfactory where only early/subtle 
inflammatory changes are present. STIR acquisitions are also time-consuming. These factors 
make the SPARCC system less attractive for clinical use.  
 
Recent work has examined the use of diffusion-weighted imaging (DWI) as a fast, quantitative 
method for quantifying SIJ inflammation (11–14). Increased sacroiliac joint apparent diffusion 
coefficient (ADC) values have been reported in both adult sacroiliitis (11–13) and sacroiliitis 
in adolescents with ERA (14), and is thought to be due to increased extracellular fluid 
(exudate) and cellular infiltration (15) in the juxta-articular bone marrow. ADC 
measurements are intrinsically more objective than visual scoring since they are derived from 
pixel values in the image itself. Importantly, recent studies have examined the use of a 
reference region-of-interest (ROI) placed on normal sacral bone to normalise ADC values, with 
the aim of minimizing between-scan variations in measured ADC (14). There is a good 
correlation between normalized ADC (nADC) measurements and SPARCC scores of 
inflammation in ERA (14).  
 
However, there have been no previous studies assessing whether DWI can be used to 
measure response to therapy in ERA. Establishing whether biomarker estimates reflect 
biological change is an essential part of quantitative imaging biomarker (QIB) validation 
(16,17).  
 
In this study, we evaluate both ADC and nADC as measures of response to tumour necrosis 
factor inhibitor (TNFi) therapy. As a primary objective, we evaluate whether the change in 
ADC/nADC after treatment is greater in responders to TNFi treatment than in non-
responders. Secondarily, we determine the extent to which change in ADC/nADC can be 
used to classify patients as responders/non-responders, and assess the correlation between 
change in nADC/ADC and change in SPARCC STIR score.  
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MATERIALS AND METHODS 
This retrospective study was covered by IRB approval from the National Research Ethics 
Service (NRES) Committee London – Bentham, England (REC ref: 11/LO/0330). Informed 
consent was waived due to the retrospective nature of the study.  
Subjects 
A local clinical adolescent rheumatology database was used to identify all those ERA patients 
with sacroiliitis who had been started on biologic therapy between January 2009 and June 
2015. We then performed a picture archiving and communication systems (PACS) search to 
identify those individuals who had undergone MRI scans of the SIJs between both before and 
after starting biologic therapy, using the imaging protocol specified below (see MRI 
technique). Patients who started on biologic treatments during this period and who had MRI 
scans both before and after starting therapy were selected for the study. All subjects fulfilled 
the International League of Associations for Rheumatology (ILAR) criteria for ERA (18) and 
were treated with either etanercept or adalimumab. The decision to scan the patients and to 
treat with biologic therapy was made as part of standard clinical care in all cases. At our 
institution, ERA patients are typically scanned at presentation, 3 months after starting 
treatment (usually methotrexate) and again after a further 3-6 months if patients are started 
on biologic therapy to confirm improvement of inflammatory changes (19). A subset of 
patients are also scanned at regular intervals (typically yearly) following this for disease 
monitoring (19). Two patients were excluded from the study because the DWI acquisition 
was not performed to protocol.   
 
MRI technique 
MRI of the SIJs was performed using a 1.5T system (Avanto; Siemens, Germany). Scan 
parameters were as follows: 
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T1 turbo spin echo (TSE) coronal: TR/TE 610/11ms, slices 18, slice thickness 3mm, FOV 
200mm; T1 TSE axial – TR/TE 610/11ms, slices 18, slice thickness 3mm, FOV 200mm, matrix 
size 256 x 256, pixel size 1mm. 
 
T1 TSE axial: TR/TE 475/11ms, slices 20, slice thickness 5mm, FOV 200mm; T1 TSE axial – 
TR/TE 610/11ms, slices 18, slice thickness 3mm, FOV 200mm, matrix size 256 x 256, pixel 
size 1mm. 
 
Short tau inversion recovery (STIR) axial: TR/TE 6070/83ms, inversion time 150ms, slices 18, 
slice thickness 5mm, FOV 200mm, matrix sixe 256 x 256, pixel size 1mm.  
 
T1 Turbo Inversion Recovery Magnitude coronal: TR/TE 4340/83ms, inversion time 150ms, 
slices 14, slice thickness 4mm, FOV 200mm, matrix size 256 x 256, pixel size 1mm.  
 
Post-contrast T1 TSE with fat saturation axial: TR/TE 619/11ms, slices 20, slice thickness 
5mm, FOV 200mm, matrix size 256 x 256, pixel size 1mm. 
Post-contrast T1 TSE with fat saturation coronal: T1 TSE fat sat coronal - TR/TE 795/11ms, 
slices 18, slice thickness 3mm, FOV 200mm, matrix size 256 x 256, pixel size 1mm. 
 
Diffusion-weighted images axial: single-shot DWI with EPI readout. TR/TE 3500/87, FOV 
316mm, matrix size 128 x 128, pixel size 2.5mm, slice thickness 8mm, averages 4, slices 17, EPI 
factor 120, b-values 0, 50, 100, 300 and 600s/mm2 with fat saturation. ADC maps were 
generated on vendor software using a standard monoexponential fit.  
 
Image Analysis 
nADC measurements were performed using a previously described technique (14), as 
follows. The central four axial slices on the ADC maps were analysed using in-house 
MATLAB [The MathWorks, Natick, MA] code. Three linear regions-of-interest (ROIs) 
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measuring 14mm were drawn across the synovial portion of each SIJ, with each ROI centred 
on the joint space. Where the AP dimensions of the joint were too small to place three ROIs, 
only two ROIs were placed. A further ‘reference’ ROI was placed on normal sacral bone to 
provide internal standardization. The normalised ADC (nADC) value of each patient was 
defined as the ratio between the mean ADC of all joint line profiles and the mean reference 
ADC.  
 
For each scan, both the ‘uncorrected’ ADC and nADC were recorded. The measurements 
were performed independently by two radiologists (KV and TB, with seven and four years of 
musculoskeletal MRI experience respectively); the mean of the two radiologists’ scores was 
used for the analysis.  
 
The change in ADC after therapy (ΔADC) was defined as: 
 
ΔADC = ADCpre – ADCpost 
 
and the change in nADC after therapy was: 
 
ΔnADC = nADCpre – nADCpost 
 
Note that positive ΔADC and ΔnADC values represent a reduction in the post-treatment 
nADC (i.e. improving inflammation). 
 
The SPARCC STIR scoring technique (10) was modified for use on axial rather than coronal 
images, to facilitate comparison between STIR images and ADC maps as previously 
described (14). On each of the central six axial slices, the SIJ was divided into four quadrants. 
Increased STIR signal was given a score of 1 per quadrant and normal signal was scored 0. 
For each slice, an additional score of 1 per joint was given for deep or intense lesions (10). 
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Each patient received a maximum score of 12 per slice, and a maximum total of 72. Scoring 
was performed independently by two radiologists (MHC and TB) with over twenty years and 
four years of musculoskeletal MRI experience respectively, who were blinded to clinical data 
and the diffusion scores. The mean score from the two sets of measurements was used for the 
analysis. The change in STIR score after therapy was defined as: 
 
ΔSTIR = STIRpre – STIRpost 
 
Response Classification 
Radiological response classification was based on changes in SPARCC STIR score after 
treatment. Specifically, based on previous studies defining a ‘minimally important change’ 
for SPARCC scores of sacroiliac joint inflammation (20), patients were classified as radiological 
responders if the mean STIR score from the two observers improved by 2.5 or more, and 
radiological non-responders otherwise. This threshold was derived using a receiver operating 
characteristic (ROC) analysis to determine the STIR score change which would predict 
‘minimally important’ changes in inflammation (as determined by a radiologist) with the 
highest degree of sensitivity and specificity (20).  
 
Each patient was classified as either a clinical responder or clinical non-responder to TNFi 
therapy using a retrospective physician global assessment (PGA). Specifically, a specialist 
consultant adolescent rheumatologist (NA) who was blinded to SPARCC, ADC and nADC 
scores reviewed the electronic medical record to determine clinical symptoms at the time each 
scan was acquired (i.e. both the pre-TNFi and post-TNFi scans) to define a composite global 
assessment of response to treatment. Patients who required emergency steroid treatment 
(defined as a course of systemic steroids to treat a flare – i.e. oral prednisolone, intramuscular 
or intravenous methylprednisolone) or a switch to an alternative TNFi at the time of the 
second scan were classified as non-responders. Patients who had only marginally improved 
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[defined as an improvement in PGA of less than 30%, mirroring the PGA component of the 
ACR Pedi 30 criteria (21,22)] were also classified as non-responders.  
 
In cases where clinical and radiological response classifications were discordant, we reviewed 
the individual STIR, nADC and ADC scores to determine the reasons for disagreement. 
Biochemical markers of inflammation (specifically C-reactive protein and erythrocyte 
sedimentation rate) were not used as response classifiers since there are no accepted criteria, 
and because these markers are insensitive as measures of inflammation (23). 
 
Statistical Analysis 
The Mann-Whitney-Wilcoxon test was used for between-group comparisons. The correlation 
between change in ΔADC/ΔnADC and ΔSTIR was evaluated using Spearman’s rho. Receiver 
operating characteristic analyses were performed using MATLAB’s perfcurve function to 
assess sensitivity and specificity for determining response using both ΔADC and ΔnADC 
(using both clinical and radiological response classifications). Repeatability was assessed 
separately for pre-treatment and post-treatment nADC and ADC measurements using 
intraclass correlation coefficient (ICC) and Bland-Altman 95% limits of agreement. 
RESULTS 
Demographics 
Twenty-two patients were recruited, with a mean age at biologic initiation of 17y4m. 
Eighteen subjects were male (mean age 17y3m), and four were female (mean age 17y6m). The 
mean interval from pre-treatment scan to the initiation of biologic therapy was 4m (range 1m 
to 8m). The mean interval from start of biologic to post-treatment scan was 1y1m (range 5m 
to 2y6m).  
 
Disease Response: Radiological Classification 
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Of the 22 patients in the cohort, 18/22 patients (82%) demonstrated a STIR score 
improvement of  2.5 and were classified as radiological responders; 4/22 (18%) were 
classified radiological non-responders. Uncorrected ADC and nADC values before and after 
treatment, classified by radiological response, are shown in Table 1 and Figure 1.  
 
Baseline ADC values were significantly higher pre-treatment in radiological responders 
compared to non-responders (p=0.03). After treatment, there was a decrease in ADC values in 
responders and an increase in non-responders, such that post-treatment ADC values were 
higher in non-responders than in responders (p=0.16). Furthermore, the change in ADC 
values (ΔADC) was significantly greater in responders than in non-responders (p<0.01).  
 
Baseline nADC values were also higher in responders than in non-responders, although this 
difference was non-significant (p=0.31). Following treatment, nADC values were marginally 
lower in responders than in non-responders, again non-significant (p=0.22). There was a 
reduction in nADC values after treatment in both responders (median ΔnADC = 0.27) and 
non-responders (median ΔnADC = 0.10). The change in nADC values (i.e. ΔnADC) was 
greater in responders than non-responders; this difference was borderline-significant 
(p=0.055).  
 
Disease Response: Clinical Classification 
Of the 22 patients in the cohort, 18/22 patients (82%) were classified as clinical responders, 
and 4/22 (18%) were classified as clinical non-responders. Of the clinical non-responders, two 
patients had also been classified as radiological non-responders.  ADC and nADC values 
before and after treatment, classified by clinical response, are shown in Table 2 and Figure 2.  
 
There was no significant difference in baseline ADC values between responders and non-
responders (p=0.90). Post-treatment ADC values were higher in non-responders, although 
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this difference was again non-significant (p=0.097). There was no significant difference in the 
change in ADC values (i.e. ΔADC) between responders and non-responders (p=0.33). 
 
There was no significant difference in baseline nADC values between responders and non-
responders (p=0.77). Following treatment, nADC values were significantly lower in 
responders than in non-responders (p<0.01). Accordingly, there was a reduction in nADC 
values in clinical responders (median ΔnADC = 0.21) and an increase in nADC values in non-
responders (median ΔnADC = -0.12); the difference between these groups was borderline-
significant (p=0.089).  
 
Receiver operating characteristic analysis 
Using radiological criteria for response classification: 
nADC: Any decrease in nADC after treatment was 89% sensitive and 75% specific for 
distinguishing radiological responders (i.e. those with a reduction in SPARCC score ≥2.5) 
from radiological non-responders. The area under the ROC curve (ROC AUC) was 0.82, with 
a sensitivity of 89% and specificity of 75% at the optimal operating point (Figure 3).  
ADC: Any decrease in ADC after treatment was 67% sensitive and 100% specific for 
distinguishing radiological responders from radiological non-responders. ROC AUC was 
0.97, with a sensitivity of 100% and specificity of 75% at the optimal operating point.  
 
Using clinical criteria for response classification: 
nADC: Any decrease in nADC after treatment was 83% sensitive and 50% specific for 
distinguishing clinical responders from clinical non-responders. ROC AUC was 0.78, with a 
sensitivity of 95% and a specificity of 50% at the optimal operating point.  
ADC: Any decrease in ADC after treatment was 50% sensitive and 50% specific for 
distinguishing clinical responders from clinical non-responders. ROC AUC was 0.67, with a 
sensitivity of 95% and a specificity of 50% at the optimal operating point (Figure 3). 
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nADC as a Continuous Response Measure 
Figure 4 shows the relationship between change in ADC/nADC (ΔADC and ΔnADC 
respectively) and change in SPARCC STIR score (ΔSTIR) after TNFi treatment. There was a 
significant, positive correlation between ΔADC and ΔSTIR (R=0.60, p=0.031) and between 
ΔnADC and ΔSTIR (R=0.55, p<0.01). 
 
Repeatability 
For ADC, the pre-treatment ICC was 0.98 (Bland-Altman 95% limits of agreement  110 x 10-6 
mm2/s) and the post-treatment ICC was 0.96 (Bland-Altman 95% limits of agreement  145 x 
10-6 mm2/s). For nADC, the pre-treatment ICC was 0.93 (Bland-Altman 95% limits of 
agreement  0.52) and the post-treatment ICC was 0.81 (Bland-Altman 95% limits of 
agreement  0.43).  
 
DISCUSSION 
Several previous studies have investigated DWI as a tool for monitoring sacroiliac joint 
inflammation, both in adults with ankylosing spondylitis (11–13) and in adolescents with 
ERA (14). However, to our knowledge there are no previous studies evaluating the change in 
ADC/nADC after TNFi therapy in ERA. The results of this study suggest that changes in 
ADC/nADC after TNFi therapy reflect response to treatment as defined using radiological 
criteria, and may also reflect response to treatment as defined clinically. Accordingly, changes 
in ADC/nADC could predict response with a high degree of sensitivity and specificity, and 
were positively correlated with changes in SPARCC STIR score.  
 
DWI is an attractive tool for measuring response since it is more objective than STIR scoring 
or clinical assessment as it relies on pixel values in the image itself. Unlike STIR images, ADC 
maps could potentially be analysed automatically without the need for interpretation by a 
radiologist, making quantitative measurements of inflammation severity more readily 
available in the clinic. DWI is also faster than STIR imaging (typically three minutes 
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compared to six minutes), and could help to minimize scan time for patients with stiff, 
painful joints. Although serial MRI scans of the sacroiliac joints are not used routinely in all 
rheumatological centres, images that be can be acquired and analysed quickly and objectively 
may lower the threshold for introduction into clinical practice, thereby facilitating patient-
specific therapeutic decision making. These methods could also be used to evaluate adult 
spondyloarthritis and to image other joints.  
 
An interesting result of our study is that pre-treatment ADC scores were significantly higher 
in radiological responders compared to non-responders (p=0.03). This raises the possibility 
that baseline ADC measurement could be used to determine the likelihood of response to 
treatment in individual patients. It may be that TNFi therapy is intrinsically more effective in 
patients with severe inflammation as opposed to those with lower-grade, more indolent 
disease. Further work in a larger cohort is needed to verify this finding.  
 
In this study, ADC and nADC were more accurate predictors of radiological response than of 
clinical response. This may be because clinical assessment is only an indirect measure of 
inflammation – by contrast, STIR scoring and ADC/nADC directly measure inflammation 
(against which TNFi treatment is directed) and are not influenced by psychological, social or 
biomechanical factors. Accordingly, previous studies have found clinical assessment to be an 
insensitive tool for diagnosing sacroiliitis (8) and that JIA patients in clinical remission 
frequently have evidence of ongoing inflammation on MRI scans (24). Occult inflammation 
could be prognostically important because of the potential for structural damage and fusion 
(25,26) which contribute to disability (27). 
 
Here, we performed separate measurements and analyses for ‘uncorrected’ ADC and for 
normalised ADC (nADC) values, both of which have previously been used to measure 
sacroiliiac joint inflammation (11–14). Our results suggest that these measurements may have 
different characteristics. For example, ADC measurements demonstrated superior inter-
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observer repeatability compared to nADC measurements. Repeatability is clearly a desirable 
biomarker characteristic (16) but this study has not evaluated or compared the reproducibility 
of ADC and nADC. Reproducibility might be expected to be greater for nADC since 
normalization is designed to account for variations in image intensity between different scans 
and between imaging platforms (28–30). This issue could be addressed by performing repeat 
scans in the same individual in different sessions and across different imaging platforms. 
 
Establishing that biomarkers reflect biological change is a key step in imaging biomarker 
validation; in this study, visual STIR scoring was used as a reference standard for biologic 
change (16). However, visual STIR scoring cannot be regarded as a true ‘gold-standard’ for 
validation of ADC/nADC because ADC measurements reflect a variety of biological 
processes which are not assessed using STIR scoring. ADC measurements are influenced by 
cell membrane permeability, macromolecular packing and viscosity (31). Additionally, fat 
metaplasia in areas of resolved inflammation after biologic therapy produces areas of low 
signal on ADC maps which are not measured using STIR scoring. ADC histogram analysis 
(32–34) could potentially be used to separately quantify active inflammation and fat 
metaplasia.  
 
Some limitations in this work have arisen due to the retrospective nature of the study. Firstly, 
this was a retrospective study and the sample size was small relatively small. We also had no 
control over the time interval between patients starting TNFi therapy and the second scan. 
ERA is a chronic disease and SIJ changes are expected to occur over a long timescale, but it 
would be desirable to scan the patients at a fixed interval after starting treatment (preferably 
six months post-TNFi). Thirdly, clinical response classification was performed 
retrospectively, which limits the accuracy of response measurement. Nonetheless, clinical 
response measurements are intrinsically susceptible to a multitude of physical, psychological 
and social factors, and therefore a degree of discrepancy with radiological measures of 
inflammation is expected. Ideally, we would collect a variety of clinical scores (including 
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Physician Global Assessment, Bath Ankylosing Spondylitis Index, and quality of life 
measures) to allow for a more complete assessment of clinical response (35,36). Whilst our 
results are promising, we aim to perform definitive biological validation in a larger, 
prospective study. Finally, ADC measurements in the sacroiliac joint vary with maturity (37) 
and further work will be required to develop strategies to account for maturity-related ADC 
changes.  
 
In conclusion, we have demonstrated that DWI measurements reflect response to treatment 
in adolescent ERA patients with sacroiliitis as defined using both clinical and radiological 
criteria. DWI is fast, objective and may facilitate patient-specific therapeutic decision making.  
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FIGURE CAPTIONS 
Figure 1 – Response plots for nADC and ADC by radiological response. Pre- and post-
treatment nADC and ADC values are shown for all 22 patients, classified according to 
radiological response. Patients whose nADC/ADC reduced between after treatment are 
shown in green, whilst patients whose nADC/ADC increased are shown in red. ADC values 
have units mm2/s x 10-6.  
 
Figure 2 – Response plots for nADC and ADC by clinical response. Pre- and post-treatment 
nADC and ADC values are shown for all 22 patients, classified according to clinical response. 
Patients whose nADC/ADC reduced between after treatment are shown in green, whilst 
patients whose nADC/ADC increased are shown in red. ADC values have units mm2/s x 10-
6. 
 
Figure 3 – Receiver operating characteristic (ROC) analysis. Changes in ADC and nADC (i.e. 
ΔADC and ΔnADC) were used to discriminate responders from non-responders. Separate 
curves are shown for response classification using clinical and radiological criteria. The 
optimal operating points are arrowed in blue for nADC and in red for ADC.  
 
Figure 4 – Scatterplot showing the relationship between change in ADC and nADC (ΔADC 
and ΔnADC respectively) and change in SPARCC STIR score (ΔSTIR) after TNFi treatment.  
Positive values for ΔADC, ΔnADC and ΔSTIR represent improving inflammation, while 
negative values represent worsening inflammation. 
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